7th European HIV Drug Resistance Workshop

Conference Reports for NATAP


7th European HIV Drug Resistance Workshop March 25-27, 2009 Stockholm

	Ultradeep pyrosequencing and phenotypic analysis to characterize the V3 genetic diversity among HIV-1 primary isolates and their responses to maraviroc (06/16/09) Virologic Outcome After geno2pheno Versus Trofile: Controversy on Using Genotype to Predict Coreceptor Use Before Maraviroc - Written by Mark Mascolini (04/01/09) Comparison of two etravirine weighted genotypic scores with phenotypic susceptibility and virological response data (03/31/09) No Darunavir & Kaletra Major PI Mutations in ARTEMIS 96 Weeks (03/31/09) Low-Level Transmitted K103N Mutation Predicts Virologic Failure - Written by Mark Mascolini (03/31/09) No Resistance to Darunavir or Lopinavir After 96 Weeks in ARTEMIS - Written by Mark Mascolini (03/31/09) Weighted Genotyping Scores Work Equally Well in Predicting Response to Etravirine - Written by Mark Mascolini (03/31/09) Weighted Genotypic Score Predicts Response to Maraviroc in MOTIVATE Trials - Written by Mark Mascolini (03/30/09) Minority Clusters of K103N Mutation in Antiretroviral-Naive People in B & non-B Subtypes - Written by Mark Mascolini (03/27/09) Genotyping for Coreceptor Use Concordant With Trofile in PBMCs and Plasma: from Jules- genotyping this falls short - Written by Mark Mascolini (03/27/09) HIV-Induced CD4 Declines Affect Immune Response to HBV in Untreated People - Written by Mark Mascolini - (03/27/09) Viral Loads--But Not Transmission of Resistant Virus--Falling in Italian Cohort - Written by Mark Mascolini - (03/27/09) Resistance Testing Is Not Standard-of-Care After Antiretroviral Failure in Europe - Written by Mark Mascolini - (03/27/09) Cumulative Resistance Score Gives Broader View of Potential Antiretroviral Activity - Written by Mark Mascolini - (03/27/09)